-
Jan 17, 2025 | 
nature.com | Cristina Legido-Quigley |Timo Minssen |Filip Ottosson |Peter Rossing
Contemporary healthcare is undergoing a transition, shifting from a population-based approach to personalized medicine on an individual level1. In October 2023, the European Partnership for Personalized Medicine was officially launched2 to communicate the benefits of this approach to citizens and healthcare systems in member countries. The main debate revolves around the inconsistency in regulatory changes within personal data access and its potential commercialization.
-
Jan 17, 2025 | 
onlinelibrary.wiley.com | Robert J. Mentz |Stefan Anker |Bertram Pitt |Peter Rossing
Supporting Information Filename Description ejhf3569-sup-0001-Supinfo.docxWord 2007 document , 620.3 KB Appendix S1. Supporting Information. References 1, , . Detecting and treating lung congestion with kidney failure. Clin J Am Soc Nephrol 2022; 17: 757–765. https://doi.org/10.2215/cjn.14591121 2, , , . Volume overload and adverse outcomes in chronic kidney disease: Clinical observational and animal studies. J Am Heart Assoc 2015; 4:e001918.
-
Jan 2, 2025 | 00573-5/abstract&sz=64)
thelancet.com | Sara Stinson |Roman Thielemann |Helene Bæk Juel |Peter Rossing
KeywordsLipidomicsGenome-wide association studyChildrenCardiometabolic riskMendelian randomisationEvidence before this studyHigh-throughput lipidomics has enabled detailed mapping of individual molecular lipid species, offering a comprehensive snapshot of lipid metabolism. Observational studies have identified several lipid species as biomarkers for cardiovascular disease and type 2 diabetes in adults.
-
Oct 28, 2024 | 
nature.com | Pardeep S. Jhund |Meike Brinker |Peter Kolkhof |Michele Senni |Sanjiv Shah |Adriaan A. Voors | +3 more
Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03264-4, published online 1 September 2024. In the version of the article initially published, the first three columns of the “New-onset atrial fibrillation” row of Fig. 1 originally read “286 (3.0)”, “1.3”, “345 (3.6)” and have now been amended to “286 (3.9)”, “1.4”, “345 (4.7)” in the HTML and PDF versions of the article.
-
Sep 20, 2024 | 
nature.com | Sara Stinson |Min Jung Kim |Trine Nielsen |Peter Rossing |Maja Thiele |Aleksander Krag | +2 more
AbstractPediatric obesity is a progressive, chronic disease that can lead to serious cardiometabolic complications. Here we investigated the peripheral lipidome in 958 children and adolescents with overweight or obesity and 373 with normal weight, in a cross-sectional study. We also implemented a family-based, personalized program to assess the effects of obesity management on 186 children and adolescents in a clinical setting.
-
Sep 8, 2024 | 
nature.com | Tina Okdahl |Davide Bertoli |Klaus Krogh |Christian Hansen |Joachim Størling |Peter Rossing | +5 more
AbstractChronic inflammation is associated with diabetes and contributes to the development and progression of micro- and macrovascular complications. Transcutaneous vagus nerve stimulation (tVNS) has been proposed to reduce levels of circulating inflammatory cytokines in non-diabetics by activating the cholinergic anti-inflammatory pathway. We investigated the anti-inflammatory potential of tVNS as a secondary endpoint of a randomized controlled trial in people with diabetes (NCT04143269).
-
Sep 3, 2024 | 
onlinelibrary.wiley.com | Gerasimos Filippatos |Stefan Anker |George Bakris |Peter Rossing
Introduction Cardiovascular disease (CVD) and its related morbidity and mortality is associated with left ventricular hypertrophy (LVH).1-3 Hypertension is common in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D); patients with these co-morbidities have a high prevalence of left ventricular (LV) hypertrophy.1-3 Finerenone is a selective, nonsteroidal mineralocorticoid receptor antagonist (MRA).
-
Sep 1, 2024 | 
nature.com | Pardeep S. Jhund |Meike Brinker |Peter Kolkhof |Michele Senni |Sanjiv Shah |Adriaan A. Voors | +3 more
AbstractCardiovascular-kidney-metabolic syndrome is an emerging entity that connects cardiovascular diseases, chronic kidney disease, and diabetes. The non-steroidal mineralocorticoid receptor antagonist, finerenone, has been studied in three prospective randomized clinical trials of patients with cardio-kidney-metabolic syndrome: FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF.
-
Aug 1, 2024 | 
jacc.org | Richard E. Pratley |Katherine R. Tuttle |Peter Rossing |Søren Bo Rasmussen
Introduction Heart failure (HF) affects an estimated 64 million people worldwide.1 The increasing global prevalence of HF is due to an aging population, as well as increasing rates of hypertension, coronary artery disease, obesity, type 2 diabetes (T2D), and chronic kidney disease (CKD).2-8 When T2D and CKD coexist, the risk for HF and mortality is increased beyond that of either condition alone.9 Therefore, developing better strategies for HF prevention and treatment in high-risk patients...
-
Jul 9, 2024 | 
healio.com | Michael Monostra |Richard Smith |Peter Rossing
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Of a small group of 47 adults with type 1 diabetes in NHANES, 20 met the criteria for having CKD. Researchers said increased CKD surveillance and treatment strategies are needed in type 1 diabetes.
